UK Guide Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for type 2 diabetes mellitus, not weight management
GLP-1-based therapies and resmetirom operate through distinct and potentially complementary mechanisms: while resmetirom exerts direct hepatic effects by activating THR- to enhance mitochondrial function, reduce hepatic lipogenesis, and promote lipid oxidation specifically in hepatocytes, GLP-1 RAs and multi-agonists address the upstream metabolic drivers of MASLD including insulin resistance, obesity, and systemic inflammation
Although these three types of cells each have distinct functions, it is more important to note that the somatostatin, glucagon, and insulin they secrete work together through mutual regulation and feedback mechanisms to maintain blood glucose balance and overall metabolic homeostasis.253,254 GLP-1 usually refers to GLP-1(7-36), a peptide chain consisting of 36 amino acids and the primary active molecule.255 GLP-1(7-36) stimulates the release of paracrine glucagon inhibitory factors by activating GLP-1R on -cells and -cells.241 DPP-4 cleaves GLP-1(7-36) at the 8th position, generating GLP-1(936)
Iron, calcium, and vitamin D round out the essential micronutrient trio for GLP-1 users
